20,41 €
Deine Einschätzung
Intellia Therapeutics Inc Aktie
Was spricht für und gegen Intellia Therapeutics Inc in den nächsten Jahren?
Pro
Kontra
Rendite von Intellia Therapeutics Inc im Vergleich
Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
---|---|---|---|---|---|---|---|
Intellia Therapeutics Inc | -0,63 % | 9,96 % | -2,93 % | -36,19 % | -29,05 % | -84,67 % | 53,40 % |
Chromadex Corp | 3,13 % | 4,43 % | 12,24 % | 150,00 % | 150,00 % | -37,14 % | -12,73 % |
Organovo Holdings Inc. | 1,09 % | -6,82 % | -16,33 % | -67,37 % | -56,04 % | -93,04 % | -91,14 % |
Polynovo Ltd | -3,29 % | -2,00 % | -3,92 % | 96,00 % | 47,74 % | 20,49 % | 6,49 % |
Kommentare
News
The Bull Case for Intellia Therapeutics Stock Just Got Even Stronger
Intellia Therapeutics (NASDAQ: NTLA) just published some new data that suggests the company has what it takes to continue being a leader in the gene editing space. While there's still a lot of work
Cathie Wood Goes Bargain Hunting: 2 Stocks She Just Bought
Cathie Wood is known for two things: picking out innovators that will go on to score a win over the long run, and getting in on these stocks at a great price. The founder and chief executive officer
These 2 Words Are Why Intellia Therapeutics Could Be a Smart Buy Right Now
On June 2, Intellia Therapeutics' (NASDAQ: NTLA) CEO John Leonard remarked on the biotech's progress with one of its early-stage clinical programs called NTLA-2002, uttering two very important words